Skip to main content

Sanna Bastiano's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Feb 3, 2022

Accession no.
0001209191-22-006792
Filed
Feb 3, 2022
Trade date
Feb 1-2, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market sales total $261.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sanna BastianoCIK 0001829069Officer (EVP, Cell & Genetic Therapies)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 1, 2022Common StockAGrant or awardAcquired+11,628$0.00$044,204Direct
Feb 1, 2022Common StockAGrant or awardAcquired+12,314$0.00$056,518Direct
Feb 1, 2022Common StockFTax withholdingDisposed−526$243.64−$128,154.6455,992Direct
Feb 2, 2022Common StockSSaleDisposed−670$250.04F4,F5−$167,526.855,322Direct
Feb 2, 2022Common StockSSaleDisposed−141$251.47F5,F6−$35,457.2755,181Direct
Feb 2, 2022Common StockSSaleDisposed−149$253.07F5,F7−$37,707.4355,032Direct
Feb 2, 2022Common StockSSaleDisposed−64$253.95F5,F8−$16,252.854,968Direct
Feb 2, 2022Common StockSSaleDisposed−16$254.54F5,F9−$4,072.6454,952Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97).

Referenced by the price of 1 transaction in Table I.

F5

Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 5 transactions in Table I.

F6

Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85).

Referenced by the price of 1 transaction in Table I.

F7

Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42).

Referenced by the price of 1 transaction in Table I.

F8

Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42).

Referenced by the price of 1 transaction in Table I.

F9

Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80).

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)